DRX 254Alternative Names: Deuterated CC 122; Deuterium stabilised CC 122; DRX-254
Latest Information Update: 10 Apr 2015
At a glance
- Originator DeuteRx
- Class Antineoplastics
- Mechanism of Action Signal transduction pathway modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Haematological malignancies; Solid tumours